Quelle prise en charge optimale pour un sarcome du cordon spermatique en 2018 ?
Sébastien Carrère, Sylvie Bonvalot(Dana-Farber Cancer Institute), Pascal Meeus(Centre Léon Bérard), Nelly Firmin(Inserm), E. Stoeckle(Institut Bergonié), Gauthier Decanter(Centre Oscar Lambret), R. Tétreau(Institut de Recherche en Cancérologie de Montpellier), Charles Honoré(Institut Gustave Roussy), Brigitte Meunier(Bodmin Hospital), Didier Cupissol(Institut de Recherche en Cancérologie de Montpellier), Gwénaël Ferron(Centre Hospitalier Universitaire de Toulouse), François Quénet(Institut de Recherche en Cancérologie de Montpellier), M. Fau(Institut de Cancérologie de Lorraine), Jean‐Baptiste Delhorme(Hôpitaux Universitaires de Strasbourg), C. Llacer(Inserm), Dimitri Tzanis(Université Paris Cité)
Cited by 3
Related Papers
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|Annals of Oncology|2021|978
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|812
Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|751
Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|641